Search

EHA-SWG Scientific Meeting on Pediatric Hematology 2022

On April 7-9, 2022 the EHA-SWG Scientific Meeting on Pediatric Hematology was successfully held at the NH Collection Vittorio Veneto hotel in Rome.

Read more

European Hematology Association publishes new journal with Wolters Kluwer

The European Hematology Association, the largest Europe-based association of hematologists, launched its new journal HemaSphere with publisher Wolters Kluwer at the 22nd Annual Congress of EHA in Madrid.

Read more

Daratumumab Shows Remarkable Benefit in Relapsed or Refractory Multiple Myeloma in the POLLUX Study

Daratumumab is a fully human monoclonal antibody that binds to a novel target on myeloma cells.

Read more

Press Release: Economic burden of blood disorders in EU is €23 billion

The economic burden of blood disorders across the European Union, Iceland, Norway and Switzerland amounts to €23 billion per year.

Read more

EHA statement on coronavirus (COVID-19)

The European Hematology Association (EHA) closely monitors the latest developments on the spreading of the Coronavirus (COVID-19).

Read more

Virtual: EHA-PTHiT Hematology Mini Tutorial - a report

VIRTUAL: EHA-PTHiT Hematology Mini Tutorial

April 12 -13, 2021

Meeting Chairs:

Prof G Gaidano (European Hematology Association)
Prof I Hus (Polish Society of Hematology and Transfusion)
Prof T Robak (Polish Society of Hematology and Transfusion)
As a prelude to the full Tutorial planned for later this…

Read more

EHA statement on coronavirus (COVID-19)

The European Hematology Association (EHA) closely monitors the latest developments on the spreading of the Coronavirus (COVID-19).

Read more

In Memoriam Anneke Brand

Picture: Ineke Oostveen

 

On Sunday, November 21, 2021, Anneke Brand, MD, PhD, emeritus professor at Leiden University Medical Center (LUMC), passed away suddenly. The European Hematology Association community is deeply saddened by Anneke’s passing.

Read more

Improved survival for adult Acute Lymphoblastic Leukemia (ALL) patients

Historical survival for patients 18-45 years with ALL is approximately 40 %. However the event free survival for ALL patients 18-45 years has improved to 73% following implementation of the NOPHO ALL2008 protocol in July 2008.

Read more